Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719791 | 1.00 | LMNA (0.54) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL1670578 | 1.00 | LMNA (0.54) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL31491210 | 0.92 | ALDH1A1 (0.47) | LMNACYP2D6MAPK1CA1CA2 | |
| SCHEMBL6447396 | 0.90 | LMNA (0.52) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL3071 | 0.90 | LMNA (0.52) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL719256 | 0.90 | LMNA (0.52) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL7758366 | 0.89 | LMNA (0.51) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL715653 | 0.88 | LMNA (0.50) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL7354344 | 0.88 | LMNA (0.50) | LMNAMAPTCYP2D6MAPK1CA1 | |
| SCHEMBL717091 | 0.88 | LMNA (0.50) | LMNAMAPTCYP2D6MAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102972-A1 | PALLADIUM-PLATED/GOLD-PALLADIUM-PLATED COPPER BONDING WIRE WITH HIGH CORROSION RESISTANCE AND HIGH CONDUCTIVITY, AND PRODUCTION PROCESS THEREFOR | 上海万生合金材料有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-119153426-B | High corrosion resistance high conductivity palladium plating/gold plating palladium copper bonding wire and production process thereof | 上海万生合金材料有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119465325-A | Electroplating method of molybdenum-copper material | 余姚市爱迪升电镀科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-119243275-A | Environment-friendly pulse electroplating method | 深圳市金源康实业有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-222263523-U | Perovskite solar cell | 旗滨新能源发展(深圳)有限责任公司 | 2024-12-27 | — | — | CN | claimed |
| CN-119153426-A | High corrosion resistance high conductivity palladium plating/gold plating palladium copper bonding wire and production process thereof | 上海万生合金材料有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-115746213-B | Anti-fouling resin and preparation method thereof | 深圳市通泰盈科技股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118326465-B | Nickel-palladium-gold electroplating surface treatment liquid suitable for packaging substrate | 深圳创智芯联科技股份有限公司 | 2024-08-06 | — | — | CN | claimed |
| CN-118326465-A | Nickel-palladium-gold electroplating surface treatment process formula suitable for packaging substrate | 深圳创智芯联科技股份有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117758327-B | Gold-tin electroplating solution for eutectic welding | 珠海市创智成功科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117758327-A | Gold-tin electroplating solution for eutectic welding | 深圳创智芯联科技股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-115746213-A | Anti-fouling resin and preparation method thereof | 深圳市通泰盈科技股份有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-20150045496-A1 | THERMO-REVERSIBLE POLYBUTADIENE RUBBER BLEND WITH SELF-HEALING NATURE | RELIANCE INDUSTRIES LIMITED (IN) | 2015-02-12 | — | — | US | claimed |
| WO-2013164843-A1 | THERMO-REVERSIBLE POLYBUTADIENE RUBBER BLEND WITH SELF-HEALING NATURE | RELIANCE INDUSTRIES LTD. (IN) | 2013-11-07 | — | — | WO | claimed |
| WO-2026102972-A1 | PALLADIUM-PLATED/GOLD-PALLADIUM-PLATED COPPER BONDING WIRE WITH HIGH CORROSION RESISTANCE AND HIGH CONDUCTIVITY, AND PRODUCTION PROCESS THEREFOR | 上海万生合金材料有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | RECLUDIX PHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-4397844-A | Antigen derivatives and processes for their preparation | CIBA-GEIGY CORPORATION (US) | 1983-08-09 | — | — | US | disclosed |
| EP-0053816-A1 | 1-Sulfo-2-oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| US-4028401-A | (Substituted)ureidoacetohydroxamic acids | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | STAT6, STAT5A, STAT3 | LMNA 3074/4885MAPT 4469/4885CYP2D6 2442/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | LMNA 4735/4885MAPT 2224/4885CYP2D6 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.